Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson’s Disease

International Journal of Molecular Sciences 2026 Open access

Read full text
Authors: Mireia Toledano-Pinedo, Alicia Porro-Pérez, Linda Schäker-Hübner, Daniel Diez‐Iriepa, Isabel Iriepa, Agata Siwek, Małgorzata Wolak, Grzegorz Satała, Andrzej Jacek Bojarski, Agata Doroż-Płonka, Jadwiga Handzlik, Justyna Godyń
+16 more Patrick Dallemagne, Christophe Rochais, Audrey Davis, Marc Since, Belén Pérez, Aina Bellver-Sanchís, Alba Irisarri, Mercè Pallàs, Cristina Solana‐Manrique, Francisco López-Muñoz, Lhassane Ismaïli, Christian Griñán-Ferré, Nuria Paricio, Finn Kristian Hansen, Anna Więckowska, José Marco-Contelles
DOI: 10.3390/ijms27073135
Cited by: 1
References: 47

Abstract

Herein, we have identified the polyfunctionalized 1-(phenylsulfonyl)-1H-indole-2-carboxylic acid derivative MTP150 for the treatment of neurodegenerative diseases owing to its efficacy in reducing protein aggregation, modulating matrix metalloproteinase activity, mitigating neuroinflammation, and enhancing DNA damage repair pathways across in vivo Caenorhabditis elegans models of Alzheimer’s disease, Parkinson’s disease (PD), and Huntington’s disease. Further experiments in an in vivo Drosophila model of PD showed that MTP150 increased motor performance, reduced oxidative stress levels, and restored mitochondrial function in model flies. In addition, MTP150 exhibited neuroprotective effects in PD model cells, thereby supporting its therapeutic potential for this disease.

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Sirtuins and Resveratrol in Medicine Amyotrophic Lateral Sclerosis Research

Publication details

Journal / source
International Journal of Molecular Sciences
Publisher
MDPI AG
Volume
27
Issue
7
Pages
3135–3135
Publication date
30 March 2026
Language
EN